Cross Country Healthcare reported a significant net loss in Q4 2025, primarily driven by non-cash impairment charges and tax valuation allowances following the termination of the Aya Merger Agreement. While revenue declined 24% year-over-year due to a challenging travel staffing market, the company maintained a strong debt-free balance sheet and positive operating cash flow.

Cross Country Healthcare reported first quarter 2025 financial results with consolidated revenue of $293.4 million, a decrease of 23% year-over-year. The company posted a net loss of $0.5 million and adjusted EPS of $0.06. Despite the overall revenue decline, Homecare Staffing, Physician Staffing, and Cross Country Education segments experienced growth. The company maintained a strong balance sheet with $80.7 million in cash and no debt, while continuing to work towards the pending merger with Aya Healthcare.

Cross Country Healthcare's fourth quarter revenue was $309.9 million, a 25% decrease year-over-year, but at the high end of their guidance range. The company reported a net loss of $3.8 million for the quarter, with diluted EPS at -$0.12. Non-travel businesses, including Physician Staffing, Education, and Homecare, showed continued strength.

Cross Country Healthcare's third quarter results showed stabilization across the core business with momentum in Homecare, Physician, and Education Staffing. Revenue was $315.1 million, a decrease of 29% year-over-year, and net income attributable to common stockholders was $2.6 million.

Cross Country Healthcare's second quarter results were in line with expectations, reflecting their ability to execute in a challenging environment for core nurse and allied. The company reported revenue of $339.8 million, a net loss attributable to common stockholders of $16.1 million, and adjusted EPS of $0.10.

Cross Country Healthcare reported a decrease in revenue and profitability for Q1 2024, impacted by headwinds in contingent nursing labor. Revenue was $379.2 million, a 39% decrease year-over-year. Net income was $2.7 million, and adjusted EPS was $0.19. However, the company saw growth in physician staffing and homecare staffing.

Cross Country Healthcare's Q4 2023 revenue was $414.0 million, a decrease of 34% year-over-year. Net income attributable to common stockholders was $9.0 million, and diluted EPS was $0.26. The company proactively managed its cost structure, repaid $73.9 million on the term loan, and invested over $20 million in core technologies.

Cross Country Healthcare reported a revenue of $442.3 million for Q3 2023, a 30% decrease year-over-year and an 18% decrease sequentially. Net income was $12.8 million, with diluted EPS at $0.36, and adjusted EPS at $0.39. The company highlighted growth in physician staffing, education, and homecare staffing, and the signing of a significant Intellify® agreement.

Cross Country Healthcare reported a decrease in revenue of 28% year-over-year and 13% sequentially, with a net income attributable to common stockholders of $21.3 million. However, the company's revenue and adjusted EPS exceeded guidance ranges, driven by strong growth in Physician Staffing and increased travel demand throughout the quarter. The company also repaid its term loan and repurchased shares.

Cross Country Healthcare's Q1 2023 results showed revenue of $622.7 million, a net income of $29.4 million, and diluted EPS of $0.81. The company exceeded expectations for revenue and profitability, with physician staffing revenue growing by 75%. They also signed their first Intellify vendor-neutral client contract and repurchased 1.2 million shares of common stock.

Cross Country Healthcare reported Q4 2022 consolidated revenue of $628.2 million, a slight decrease year-over-year and quarter-over-quarter. Diluted EPS was $1.05, compared to $2.07 in the prior year and $0.93 in the prior quarter. Net income attributable to common stockholders was $38.8 million, down from $77.6 million in the prior year and up from $34.8 million in the prior quarter.

Cross Country Healthcare reported strong Q3 2022 results, exceeding updated guidance ranges for revenue, Adjusted EBITDA, and Adjusted EPS. The company saw double-digit year-over-year revenue growth across both segments and repurchased 1 million shares of common stock. Consolidated revenue was $636.1 million, a 70% increase year-over-year, and net income attributable to common stockholders was $34.8 million.

Cross Country Healthcare announced strong second quarter 2022 results with revenue increasing 127% year-over-year to $753.6 million and net income attributable to common stockholders increasing 358% year-over-year to $52.9 million.

Cross Country Healthcare reported record revenue of $788.7 million, a 140% increase year-over-year, and adjusted EBITDA of $97.4 million for Q1 2022. The company's performance exceeded guidance, driven by growth across all lines of business and a record number of professionals on assignment.

Cross Country Healthcare's Q4 2021 revenue reached $640.7 million, a 197% increase year-over-year and 71% sequentially, with net income attributable to common stockholders at $77.6 million, and adjusted EPS at $1.40.

Cross Country Healthcare reported a strong third quarter with a 93% year-over-year increase in revenue, reaching $374.9 million. Net income attributable to common shareholders was $23.4 million, a substantial improvement from the prior year's net loss. Diluted EPS was $0.62, and adjusted EBITDA reached $30.1 million, or 8.0% of revenue.

Cross Country Healthcare reported a strong second quarter, with revenue up 53% year-over-year and net income of $11.5 million, a significant improvement from the prior year's net loss. The company benefited from near-record demand and a tight labor market, driving higher compensation costs.

Cross Country Healthcare reported record first-quarter revenue of $329.2 million, a 57% increase year-over-year, and net income attributable to common shareholders of $19.4 million, a significant improvement compared to the prior year's net loss. Diluted EPS was $0.53, and adjusted EPS was $0.58, reflecting strong operational performance.

Cross Country Healthcare's Q4 2020 performance demonstrated its ability to deliver critical staff and support, with revenue at $215.6 million, flat year-over-year but up 11% sequentially, and net income attributable to common shareholders at $4.6 million, a significant improvement from prior periods.

Cross Country Healthcare reported a decrease in revenue by 7% year-over-year and a net loss attributable to common shareholders of $1.3 million. The company's digital transformation remained on track with the successful deployment of a new applicant tracking system for its largest business.

Cross Country Healthcare reported a 7% increase in revenue year-over-year, driven by strong demand for their services in response to COVID-19. The company reported a net loss attributable to common shareholders of $14.2 million, and an adjusted EPS of $0.16.

Cross Country Healthcare reported a revenue increase of 7% year-over-year and 3% sequentially. The company's net loss attributable to common shareholders was $1.1 million, and diluted EPS was a loss of $0.03 per share. Adjusted EBITDA was $8.3 million, and adjusted EPS was $0.07.